Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Pharmaceutical sevices company Ergomed said it expected core earnings to be ahead of market expectations, driven by 'strong' US growth following a boost from acquisitions.
For the year ended 31 December 2021, adjusted earnings before interest, taxes, depreciation, and amortisation, or EBITDA, was expected to be ahead of current market expectations and revenue to increase 37.3% to £118.6 million year-on-year.
Revenue in the key strategic market of the US grew 59.5% over prior year on a reported basis.
This growth 'builds on acquisitions in the US in prior years which are now fully integrated,' the cmpany said.
The order book growth was up 24.2% to £240 million.
'We start 2022 with an exceptionally strong platform - a robust order book, a track record of delivery and an offering that demonstrably meets the needs of a growing market,' the company said.